Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 35

  • Showing results for orngreen m. Search instead for Ørngren M (0)
1.

Exercise in muscle disorders: what is our current state?

Preisler N, Orngreen MC.

Curr Opin Neurol. 2018 Oct;31(5):610-617. doi: 10.1097/WCO.0000000000000597. Review.

PMID:
30036194
2.

Treatment Opportunities in Patients With Metabolic Myopathies.

Ørngreen MC, Vissing J.

Curr Treat Options Neurol. 2017 Sep 21;19(11):37. doi: 10.1007/s11940-017-0473-2. Review.

PMID:
28932990
3.

Substrate kinetics in patients with disorders of skeletal muscle metabolism.

Ørngreen MC.

Dan Med J. 2016 Jul;63(7). pii: B5256.

PMID:
27399985
4.

Lactate and Energy Metabolism During Exercise in Patients With Blocked Glycogenolysis (McArdle Disease).

Ørngreen MC, Jeppesen TD, Taivassalo T, Hauerslev S, Preisler N, Heinicke K, Haller RG, Vissing J, van Hall G.

J Clin Endocrinol Metab. 2015 Aug;100(8):E1096-104. doi: 10.1210/jc.2015-1339. Epub 2015 Jun 1.

PMID:
26030324
5.

Protein-carbohydrate supplements improve muscle protein balance in muscular dystrophy patients after endurance exercise: a placebo-controlled crossover study.

Andersen G, Ørngreen MC, Preisler N, Jeppesen TD, Krag TO, Hauerslev S, van Hall G, Vissing J.

Am J Physiol Regul Integr Comp Physiol. 2015 Jan 15;308(2):R123-30. doi: 10.1152/ajpregu.00321.2014. Epub 2014 Nov 19.

6.

[Incomplete Kawasaki syndrome with a coronary artery aneurysm in an infant].

Vinding RK, Debes NM, Stantchev H, Vrang C, Orngreen MC.

Ugeskr Laeger. 2014 Jun 16;176(25). pii: V01140010. Danish.

PMID:
25352282
7.

No effect of bezafibrate in patients with CPTII and VLCAD deficiencies.

Ørngreen MC, Vissing J, Laforét P.

J Inherit Metab Dis. 2015 Mar;38(2):373-4. doi: 10.1007/s10545-014-9779-3. Epub 2014 Oct 21. No abstract available.

PMID:
25331908
8.

Endocrine function over time in patients with myotonic dystrophy type 1.

Dahlqvist JR, Ørngreen MC, Witting N, Vissing J.

Eur J Neurol. 2015 Jan;22(1):116-22. doi: 10.1111/ene.12542. Epub 2014 Aug 25.

PMID:
25155546
9.

Bezafibrate in skeletal muscle fatty acid oxidation disorders: a randomized clinical trial.

Ørngreen MC, Madsen KL, Preisler N, Andersen G, Vissing J, Laforêt P.

Neurology. 2014 Feb 18;82(7):607-13. doi: 10.1212/WNL.0000000000000118. Epub 2014 Jan 22.

10.

Aerobic training in persons who have recovered from juvenile dermatomyositis.

Riisager M, Mathiesen PR, Vissing J, Preisler N, Ørngreen MC.

Neuromuscul Disord. 2013 Dec;23(12):962-8. doi: 10.1016/j.nmd.2013.09.002. Epub 2013 Sep 12.

PMID:
24120572
11.

Lactate metabolism during exercise in patients with mitochondrial myopathy.

Jeppesen TD, Orngreen MC, Van Hall G, Vissing J.

Neuromuscul Disord. 2013 Aug;23(8):629-36. doi: 10.1016/j.nmd.2013.05.007. Epub 2013 Jul 6.

PMID:
23838278
12.

Fat and carbohydrate metabolism during exercise in phosphoglucomutase type 1 deficiency.

Preisler N, Laforêt P, Echaniz-Laguna A, Ørngreen MC, Lonsdorfer-Wolf E, Doutreleau S, Geny B, Stojkovic T, Piraud M, Petit FM, Vissing J.

J Clin Endocrinol Metab. 2013 Jul;98(7):E1235-40. doi: 10.1210/jc.2013-1651. Epub 2013 Jun 18.

PMID:
23780368
13.

Patients with medium-chain acyl-coenzyme a dehydrogenase deficiency have impaired oxidation of fat during exercise but no effect of L-carnitine supplementation.

Madsen KL, Preisler N, Orngreen MC, Andersen SP, Olesen JH, Lund AM, Vissing J.

J Clin Endocrinol Metab. 2013 Apr;98(4):1667-75. doi: 10.1210/jc.2012-3791. Epub 2013 Feb 20.

PMID:
23426616
14.

Muscle regeneration and inflammation in patients with facioscapulohumeral muscular dystrophy.

Hauerslev S, Ørngreen MC, Hertz JM, Vissing J, Krag TO.

Acta Neurol Scand. 2013 Sep;128(3):194-201. doi: 10.1111/ane.12109. Epub 2013 Feb 15.

PMID:
23410246
15.

Muscle phenotype in patients with myotonic dystrophy type 1.

Andersen G, Ørngreen MC, Preisler N, Colding-Jørgensen E, Clausen T, Duno M, Jeppesen TD, Vissing J.

Muscle Nerve. 2013 Mar;47(3):409-15. doi: 10.1002/mus.23535. Epub 2012 Nov 21.

PMID:
23169601
16.

Aerobic fitness after JDM--a long-term follow-up study.

Mathiesen PR, Ørngreen MC, Vissing J, Andersen LB, Herlin T, Nielsen S.

Rheumatology (Oxford). 2013 Feb;52(2):287-95. doi: 10.1093/rheumatology/kes232. Epub 2012 Sep 22.

PMID:
23001614
17.

Fat and carbohydrate metabolism during exercise in late-onset Pompe disease.

Preisler N, Laforet P, Madsen KL, Hansen RS, Lukacs Z, Ørngreen MC, Lacour A, Vissing J.

Mol Genet Metab. 2012 Nov;107(3):462-8. doi: 10.1016/j.ymgme.2012.08.019. Epub 2012 Aug 31.

PMID:
22981821
18.

Blocked muscle fat oxidation during exercise in neutral lipid storage disease.

Laforêt P, Ørngreen M, Preisler N, Andersen G, Vissing J.

Arch Neurol. 2012 Apr;69(4):530-3. doi: 10.1001/archneurol.2011.631.

PMID:
22491199
19.

Endocrine function in 97 patients with myotonic dystrophy type 1.

Ørngreen MC, Arlien-Søborg P, Duno M, Hertz JM, Vissing J.

J Neurol. 2012 May;259(5):912-20. doi: 10.1007/s00415-011-6277-5. Epub 2012 Feb 17.

PMID:
22349862
20.

Muscle phosphorylase kinase deficiency: a neutral metabolic variant or a disease?

Preisler N, Orngreen MC, Echaniz-Laguna A, Laforet P, Lonsdorfer-Wolf E, Doutreleau S, Geny B, Akman HO, Dimauro S, Vissing J.

Neurology. 2012 Jan 24;78(4):265-8. doi: 10.1212/WNL.0b013e31824365f9. Epub 2012 Jan 11.

PMID:
22238410

Supplemental Content

Loading ...
Support Center